Novexel SA, a pharmaceutical company, engages in the discovery and development of antibacterial and antifungal agents to treat bacterial
Novexel is a pharmaceutical company that researches and develops novel class antiinfectives for the treatment of severe and difficult to treat bacterial and fungal infections. The Company has an extensive portfolio of antibacterial and anti-fungal compounds, R&D programs, and intellectual property. Novexel’s focus is on novel antimicrobial compounds with activity against multi-resistantorganisms. Novexel’s expertise in Biology, Medicinal Chemistry, Pharmacology, Microbiology and Clinical Development positions the Company at the forefront of the discovery and development of novel therapies for infectious disease.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 25, 2007 | Series B | $65M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
NIF SMBC Ventures | — | Series B |